| 卓延红,王尤佳,陈丽民,郑春暖,陈惠琴,李艺敏,江萍,王俊杰,李永斌,黄建丽.尼妥珠单抗同步调强放射治疗对老年局部晚期子宫颈癌的安全性和有效性研究[J].中华放射医学与防护杂志,2022,42(12):928-934 |
| 尼妥珠单抗同步调强放射治疗对老年局部晚期子宫颈癌的安全性和有效性研究 |
| Safety and efficacy of nimotuzumab combined with IMRT radiotherapy in the treatment of elderly patients with locally advanced cervical cancer |
| 投稿时间：2022-09-06 |
| DOI：10.3760/cma.j.cn112271-20220906-00362 |
| 中文关键词: 尼妥珠单抗|老年|子宫颈癌|同步放化疗|安全性 |
| 英文关键词:Nimotuzumab|Elderly|Cervical cancer|Concurrent chemoradiotherapy|Safety |
| 基金项目: |
|
| 摘要点击次数: 1513 |
| 全文下载次数: 520 |
| 中文摘要: |
| 目的 探讨尼妥珠单抗联合放疗对老年局部晚期子宫颈癌患者的安全性和有效性。方法 回顾性分析福建医科大学附属漳州市医院2020年6月至2021年12月共34例尼妥珠单抗联合调强放疗或同步放化疗治疗老年局部晚期子宫颈癌患者。评价治疗后1年和2年疗效及不良反应。结果 中位随访时间13.3个月(6.1~24.3个月)。全组完全缓解(CR)24例,部分缓解(PR)8例,客观缓解率(ORR)为94.1%(32/34)。放疗前肿瘤直径(49.56±19.22) mm,尼妥珠单抗联合外照射后,肿瘤直径(19.61±14.59) mm,肿瘤退缩率(TRR)59.22%。1、2年无进展生存率(PFS)分别为84.9%、84.9%,1、2年总生存率(OS)分别为91.8%、87.2%。1、2年无病生存率(DFS)分别为91.8%、87.2%,肿瘤特异性生存率(CSS)分别为95.7%、90.9%。主要不良事件为放射性肠炎、白细胞减少、低蛋白血症、贫血。结论 尼妥珠单抗联合放疗/同步放化疗治疗老年局部晚期子宫颈癌安全有效。 |
| 英文摘要: |
| Objective To investigate the safety and efficacy of nimotuzumab combined with IMRT radiotherapy in the treatment of elderly patients with locally advanced cervical cancer (LACC).Methods A retrospective analysis was conducted for 34 elderly LACC patients treated with nimotuzumab combined with IMRT radiotherapy or concurrent chemoradiotherapy in the Zhangzhou Affiliated Hospital of Fujian Medical University from June 2020 to December 2021. The efficacy and side effects were evaluated one and two years after treatment.Results Median follow-up time was 13.3 months (6.1-24.3 months). A total of 24 cases of complete response (CR) and eight cases of partial response (PR) were achieved after treatment, with an objective response rate (ORR) of 94.1% (32/34). The tumor diameters were (49.56 ± 19.22) mm before treatment and (19.61 ± 14.59) mm after treatment, with a tumor regression rate (TRR) of 59.22%.The 1- and 2- year progression-free survival (PFS) rates were 84.9% and 84.9%, overall survival (OS) rates 91.8% and 87.2%, respectively, disease-free survival (DFS) rates 91.8% and 87.2%, respectively, and the cancer-specific survival (CSS) rates 95.7% and 90.9%, respectively. The main adverse events included radiation enteritis, leukopenia, hypoproteinemia and anemia.Conclusions Nimotuzumab combined with IMRT radiotherapy or concurrent chemoradiotherapy is safe and effective in the treatment of LACC. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|